U.S.-based Tempus AI (TEM) stock is up in early trading on Monday. Yesterday, the company received FDA clearance for its ...
3d
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
Investor's Business Daily on MSN
IBD 50's Tempus AI Pulls Back From Record High After Another FDA Clearance
Tempus AI stock surged to a record high Monday, and then dipped, after the FDA cleared its new device to help drugmakers ...
Live-seq brings longitudinal, non-destructive cell sequencing to every lab, revealing new insights into cellular behavior ...
The discovery by researchers at the Centre for Genomic Regulation (CRG) in Barcelona sets the foundation for creating new, non-invasive diagnostic tests that detect different types of cancer faster ...
In a paper published on aBIOTECH, so far, the authors have for the first time comprehensively analyzed the ...
Tempus AI Inc. shares rose after it said it received 510 (k) clearance from the Food and Drug Administration for its RNA-based in vitro diagnostic device. Its stock recently rose 5.2% to $92.85 in ...
Background Molecular genetic diagnoses are critical to prevention and treatment of inherited polyposis and colorectal cancer.
Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...
Scientists at Cold Spring Harbor Laboratory have cracked open the secrets of plant stem cells, mapping key genetic regulators in maize and Arabidopsis. By using single-cell RNA sequencing, they ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback